Lauren A Barnett1, Kelvin P Jordan2, John J Edwards3, Danielle A van der Windt4. 1. 1NIHR Research Methods Fellow,Arthritis Research UK Primary Care Centre,Research Institute for Primary Care & Health Sciences,Keele University,Staffordshire,UK. 2. 2Professor of Biostatistics,Arthritis Research UK Primary Care Centre,Research Institute for Primary Care & Health Sciences,Keele University,Staffordshire,UK. 3. 3GP Research Fellow,Arthritis Research UK Primary Care Centre,Research Institute for Primary Care & Health Sciences,Keele University,Staffordshire,UK. 4. 4Professor of Primary Care Epidemiology,Arthritis Research UK Primary Care Centre,Research Institute for Primary Care & Health Sciences,Keele University,Staffordshire,UK.
Abstract
BACKGROUND: Obesity is a major risk factor for osteoarthritis (OA) whilst there is some evidence that diabetes also increases risk. Metformin is a common oral treatment for those with diabetes. OBJECTIVE: The aim is to investigate whether metformin reduces the risk of OA. METHODS: This was a cohort study set within the Consultations in Primary Care Archive, with 3217 patients with type 2 diabetes. Patients at 13 general practices with recorded type 2 diabetes in the baseline period (2002-2003) and no prior record of OA were identified. Exposure was a prescription for metformin. Outcome was an OA record during follow up. Cox proportional hazard models with Gamma frailty term were fitted: adjusted for age, gender, deprivation, and comorbidity. RESULTS: There was no association between prescribed metformin treatment at baseline and OA (adjusted HR: 1.02, 95% CI: 0.91, 1.15). A similar non- significant association was found when allowing exposure status of prescription of metformin to vary over time.
BACKGROUND: Obesity is a major risk factor for osteoarthritis (OA) whilst there is some evidence that diabetes also increases risk. Metformin is a common oral treatment for those with diabetes. OBJECTIVE: The aim is to investigate whether metformin reduces the risk of OA. METHODS: This was a cohort study set within the Consultations in Primary Care Archive, with 3217 patients with type 2 diabetes. Patients at 13 general practices with recorded type 2 diabetes in the baseline period (2002-2003) and no prior record of OA were identified. Exposure was a prescription for metformin. Outcome was an OA record during follow up. Cox proportional hazard models with Gamma frailty term were fitted: adjusted for age, gender, deprivation, and comorbidity. RESULTS: There was no association between prescribed metformin treatment at baseline and OA (adjusted HR: 1.02, 95% CI: 0.91, 1.15). A similar non- significant association was found when allowing exposure status of prescription of metformin to vary over time.
Authors: Nicola Veronese; Cyrus Cooper; Jean-Yves Reginster; Marc Hochberg; Jaime Branco; Olivier Bruyère; Roland Chapurlat; Nasser Al-Daghri; Elaine Dennison; Gabriel Herrero-Beaumont; Jean-François Kaux; Emmanuel Maheu; René Rizzoli; Roland Roth; Lucio C Rovati; Daniel Uebelhart; Mila Vlaskovska; André Scheen Journal: Semin Arthritis Rheum Date: 2019-01-11 Impact factor: 5.532
Authors: Tara S Rogers-Soeder; Nancy E Lane; Mona Walimbe; Ann V Schwartz; Irina Tolstykh; David T Felson; Cora E Lewis; Neil A Segal; Michael C Nevitt Journal: Arthritis Care Res (Hoboken) Date: 2020-01 Impact factor: 4.794
Authors: Paul Schadler; Birgit Lohberger; Nicole Stündl; Martin Helmut Stradner; Dietmar Glänzer; Patrick Sadoghi; Andreas Leithner; Bibiane Steinecker-Frohnwieser Journal: Cartilage Date: 2020-10-07 Impact factor: 3.117
Authors: Hui Li; Xiang Ding; Robert Terkeltaub; Hang Lin; Yuqing Zhang; Bin Zhou; Ke He; Kun Li; Zhichen Liu; Jie Wei; Yuanheng Yang; Hui Xie; Chao Zeng; Guanghua Lei Journal: Arthritis Res Ther Date: 2020-02-22 Impact factor: 5.156